ME Therapeutics Holdings Inc. Provides Research and Development Update and Corporate Update
In This Article:
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, is pleased to update investors on the progress of our research and development and corporate development plans.
G-CSF Antibody Candidate Update
The Company is continuing to advance our lead anti-G-CSF antibody candidate, h1B11-12, towards a potential first-in-human clinical trial. We have initiated the development of a cell line for future good manufacturing practices (GMP) production of h1B11-12 with an experienced partner organization. We anticipate this work to be complete in the second half of 2025. Concurrently, the Company is working with its advisors to choose an appropriate patient population and trial design for its potential clinical trial to be able to conduct any potential supporting nonclinical studies that may be required.
Corporate Update
The Company is pleased to announce that we will be moving into new lab and office space in the coming weeks. The new lab will enhance our current ongoing research programs by allowing us to complement the work being carried out at our contract research partners facilities. It will also allow us to explore earlier stage drug discovery opportunities to enhance our drug pipeline. The Company expects to hire new scientific research staff in the coming weeks to design and carry out our research and development activities in our new facilities.
In addition, Company management has been exploring several potential in-licensing and partnership opportunities which we believe may enhance our existing drug development pipeline.
"We are excited with the progress we are continuing to make with our existing drug development pipeline as well as our drug discovery and in-licensing and partnership opportunities." said Salim Dhanji, PhD, Chief Executive Officer of ME Therapeutics. "We are committed to continuing the growth of the Company into a biotechnology company with a strong drug development pipeline that can provide significant value to our shareholders."
ME Therapeutics Holdings Inc.
Myeloid Enhancement (ME) Therapeutics is a preclinical stage, Vancouver based biotechnology company involved in the discovery and development of novel immuno-oncology therapeutics targeting immune suppression in cancer. Our focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells to enhance anti-cancer immunity. For more information, please visit https://www.metherapeutics.com and the Company's profile on SEDAR+ at https://www.sedarplus.ca.
